KR880007080A - 제약학적 생성물 - Google Patents

제약학적 생성물 Download PDF

Info

Publication number
KR880007080A
KR880007080A KR870013711A KR870013711A KR880007080A KR 880007080 A KR880007080 A KR 880007080A KR 870013711 A KR870013711 A KR 870013711A KR 870013711 A KR870013711 A KR 870013711A KR 880007080 A KR880007080 A KR 880007080A
Authority
KR
South Korea
Prior art keywords
formula
product
interferon
compound
pharmaceutically acceptable
Prior art date
Application number
KR870013711A
Other languages
English (en)
Other versions
KR960000432B1 (ko
Inventor
코울 마아틴
리차드 보이드 맬컴
서튼 데이븟
Original Assignee
데이빗 로버츠
비이참 그루우프 피이엘시이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데이빗 로버츠, 비이참 그루우프 피이엘시이 filed Critical 데이빗 로버츠
Publication of KR880007080A publication Critical patent/KR880007080A/ko
Application granted granted Critical
Publication of KR960000432B1 publication Critical patent/KR960000432B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Formation And Processing Of Food Products (AREA)

Abstract

내용 없음.

Description

제약학적 생성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 항바이러스 치료에 동시에, 별개로 또는 순차적으로 사용하기 위한 조합 조제물로서, 인터페론과 하기식(A)의 화합물 또는 전구-의약, 또는 상기한 것중 어느 하나의 제약학적으로 수용가능한 염, 인산 에스테르 및/또는 아실 유도체를 포함하는 제약학적 생성물.
  2. 제1항에 있어서, 생성물이 인터페론과 제1항에 정의된 바와 같은 식(A)의 화합물 또는 그 나트륨염을 포함하는 생성물.
  3. 제1항에 있어서, 생성물이 인터페론과 식(A)의 전구 의약인 하기 식(B)의 화합물 또는 그 제약학적으로 수용가능한 염, 인산 에스테르 또는 아실 유도체를 포함하는 생성물.
    상기 식에서 X는 수소이다.
  4. 제3항에 있어서, 식(B)의 화합물이 X가 수소이고 두개의 OH기들이 아세틸 유도체의 형태로 존재하는 것인 생성물.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, 인터페론이 합성제조되는 생성물.
  6. 제약학적으로 수용가능한 담체와 결합된, 제1항에 정의된 바와 같은 식(A)의 화합물 또는 전구-의약, 그 제약학적으로 수용가능한 염 및/또는 유도체(제1항 내지 제4항 중 어느 한 항에 정의된 바와 같다)와 인터페론을 포함하는 제약학적 조성물.
  7. 제6항에 있어서, 조성물이 피부에 국부적으로 적용되기 위해 배합되고 부가적 성분으로 황산 라우릴 나트륨을 함유하는 조성물.
  8. 제6항 또는 제7항에 있어서, 조성물이 식(A)의 화합물 또는 전구-의약 또는 그 제약학적으로 수용 가능한 염 및/또는 유도체(제1항 내지 제4항 중 어느 한 항에 정의된 바와 같다) mg당 인터페론 1000-200000 단위를 포함하는 조성물.
  9. 항바이러스 치료에 동시에, 별개로 또는 순차적으로 사용하기 위한 조합 조제물 제조에 있어서, 제1항 내지 제8항 중 어느 한 항에 따른 생성물 또는 제약학적 조성물의 사용.
  10. 바이러스 감염을 치료하는데 사용되는 제1항 내지 제8항 중 어느 한 항에 따른 생성물 또는 제약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870013711A 1986-12-02 1987-12-01 제약학적 생성물 KR960000432B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868628826A GB8628826D0 (en) 1986-12-02 1986-12-02 Pharmaceutical products
GB8628826 1986-12-02

Publications (2)

Publication Number Publication Date
KR880007080A true KR880007080A (ko) 1988-08-26
KR960000432B1 KR960000432B1 (ko) 1996-01-06

Family

ID=10608331

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870013711A KR960000432B1 (ko) 1986-12-02 1987-12-01 제약학적 생성물

Country Status (16)

Country Link
US (1) US4957733A (ko)
EP (1) EP0271270B1 (ko)
JP (1) JP2724711B2 (ko)
KR (1) KR960000432B1 (ko)
AT (1) ATE74011T1 (ko)
AU (1) AU606629B2 (ko)
CA (1) CA1318850C (ko)
DE (1) DE3777769D1 (ko)
DK (1) DK166715B1 (ko)
ES (1) ES2037095T3 (ko)
GB (1) GB8628826D0 (ko)
GR (1) GR3004487T3 (ko)
IE (1) IE59943B1 (ko)
NZ (1) NZ222741A (ko)
PT (1) PT86232B (ko)
ZA (1) ZA878983B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813032D0 (en) * 1988-06-02 1988-07-06 Boehringer Ingelheim Int Antiviral pharmaceutical composition
DE69021791T2 (de) * 1989-06-30 1996-05-02 American Cyanamid Co Verwendung eines phagozytise-aktievierenden Stoffes : LPS oder IL-2 zur Herstellung eines Arzneimittels zur Behandlung von Staphylococcus-aureus-Infektionen bei Kühen.
JPH03124960A (ja) * 1989-10-11 1991-05-28 Mitsubishi Electric Corp 同軸形スタータ装置
GB9015051D0 (en) * 1990-07-07 1990-08-29 Beecham Group Plc Pharmaceutical treatment
GB9326177D0 (en) * 1993-12-22 1994-02-23 Smithkline Beecham Plc Pharmaceuticals
US6124304A (en) * 1993-10-05 2000-09-26 Smithkline Beecham Plc Penciclovir for the treatment of zoster associated pain
GB9323404D0 (en) * 1993-11-12 1994-01-05 Smithkline Beecham Plc Pharmaceuticals
GB9615111D0 (en) * 1996-07-18 1996-09-04 Smithkline Beecham Plc Pharmaceuticals
WO1998023285A1 (en) * 1996-11-29 1998-06-04 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
US6165458A (en) * 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
EP1655813A1 (de) * 2004-11-09 2006-05-10 Phoenix Contact GmbH & Co. KG Befestigung für elektrische Verbindung
AU2006230269A1 (en) 2005-03-30 2006-10-05 Novartis Ag Penciclovir or famciclovir for the treatment of recurrent genital herpes with a one-day application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461757A (en) * 1983-02-23 1984-07-24 Ens Bio Logicals Inc. Dimethylaminomethylenated anti-herpes compounds
DE3485225D1 (de) * 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
DE3582399D1 (de) * 1984-09-20 1991-05-08 Beecham Group Plc Purin-derivate und ihre pharmazeutische verwendung.
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition

Also Published As

Publication number Publication date
ES2037095T3 (es) 1993-06-16
DK166715B1 (da) 1993-07-05
ATE74011T1 (de) 1992-04-15
PT86232B (pt) 1990-11-07
EP0271270A2 (en) 1988-06-15
GB8628826D0 (en) 1987-01-07
PT86232A (en) 1987-12-01
AU8191287A (en) 1988-06-02
IE873247L (en) 1988-06-02
AU606629B2 (en) 1991-02-14
JP2724711B2 (ja) 1998-03-09
GR3004487T3 (ko) 1993-03-31
DK627987A (da) 1988-06-03
ZA878983B (en) 1988-08-31
US4957733A (en) 1990-09-18
JPS63145279A (ja) 1988-06-17
CA1318850C (en) 1993-06-08
KR960000432B1 (ko) 1996-01-06
EP0271270A3 (en) 1989-09-27
NZ222741A (en) 1990-10-26
EP0271270B1 (en) 1992-03-25
DK627987D0 (da) 1987-11-30
IE59943B1 (en) 1994-05-04
DE3777769D1 (de) 1992-04-30

Similar Documents

Publication Publication Date Title
FR2361901A1 (fr) Derives de substitution de nucleotides et medicament contenant ces substances
FR2392971A1 (fr) Derives de l'acide prostanoique, leur preparation et medicament contenant ces substances
HUT38256A (en) Process for producing combined pharmaceutical compositions containing xantine derivatives and o-acetyl-salicylic acid or pharmaceutically acceptables salts
FR2377374A1 (fr) Derives acyles d'amino-acides et leur utilisation comme medicaments
FI20001231A (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
ATE115958T1 (de) Nukleoside und nukleosid-analoge, pharmazeutische zusammensetzung und verfahren für die herstellung der bestandteile.
KR880007080A (ko) 제약학적 생성물
ATE137242T1 (de) Kovalente-ther lipidnukleosid-konjugate
HU906284D0 (en) Process for the production of 24-homo-d-vitamin derivatives and medical preparations containing them as active agents
KR890003382A (ko) 항 비루스성 화합물
FR2390448A1 (fr) Derives azido d'acide penicillanique utiles dans la preparation de medicaments
KR870005004A (ko) 마크롤라이드 항생물질 유도체
ATE15048T1 (de) 4''-epi erythromycin a und seine derivate brauchbar wie antibakterielle mittel.
ES2108240T3 (es) Derivados de tiosemicarbazona de 2-formilpiridina, su preparacion y su uso como agentes antitumor.
BE902796A (fr) Ester d'acetyl carnitine, sa preparation et son utilisation.
ES2130246T3 (es) Nucleosidos terapeuticos de la serie 2',3'-didesoxi-3'-fluoro-purina.
SV1996000001A (es) Nuevas aplicaciones de dimero de lisozima
KR880013927A (ko) 피리미딘 유도체
KR900014385A (ko) 제약학적 치료
DE59104469D1 (de) Dialkoxybenzylidenkampfer-Derivate.
KR880013938A (ko) 활성 화합물들
FR2412564A1 (fr) Nouvelles 2' -n-acyl- et alkyl-6' -n-alkyl- et 6', 6' -di-n-alkyl-fortimicines a et b, utiles notamment comme antibiotiques
MX9303985A (es) Nucleosidos terapeuticos.
FR2342972A2 (fr) Derives de la purine utilisables comme medicaments pour le traitement d'infections virales
FR2396742A1 (fr) Derives de 4-homoisotwistanes et leur utilisation comme medicaments

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20091224

Year of fee payment: 15

EXPY Expiration of term